VILOXAZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3
Molecular Weight	237.2949
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=C(OCC2CNCCO2)C=CC=C1

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N

InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C13H19NO3
Molecular Weight	237.2949
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297

PubMed

Title	Date	PubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].	1986	3716711
[Apropos of atypical melancholia with Sustiva (efavirenz)].	2001 May-Jun	11488260
Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.	2002	12553493
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.	2002	11903482
Intravenous antidepressant treatment: focus on citalopram.	2002 Jun	12192466
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.	2005 Dec 9	16314157
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Narcolepsy: current treatment options and future approaches.	2008 Jun	18830438
Adjustment Disorder: epidemiology, diagnosis and treatment.	2009 Jun 26	19558652
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201
Getting the balance right: Established and emerging therapies for major depressive disorders.	2010 Sep 7	20856599

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:44:44 GMT 2023` Edited by `admin` on `Fri Dec 15 16:44:44 GMT 2023`
Record UNII	5I5Y2789ZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VILOXAZINE

Official Name

English

viloxazine [INN]

Common Name

English

Viloxazine [WHO-DD]

Common Name

English

VILOXAZINE [MI]

Common Name

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-

Systematic Name

English

(±)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE

Common Name

English

VILOXAZIN

Common Name

English

VILOXAZINE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N06AX09